

**Clinical trial results:****A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU-DAY).****Summary**

EudraCT number	2017-004915-38
Trial protocol	PL
Global end of trial date	20 January 2020

Results information

Result version number	v1 (current)
This version publication date	23 January 2021
First version publication date	23 January 2021

Trial information**Trial identification**

Sponsor protocol code	V114-017
-----------------------	----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Merck Sharp & Dohme Corp.
Sponsor organisation address	2000 Galloping Hill Road, Kenilworth, United States, 07033
Public contact	Clinical Trials Disclosure, Merck Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com
Scientific contact	Clinical Trials Disclosure, Merck Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	20 January 2020
Is this the analysis of the primary completion data?	Yes
Primary completion date	20 January 2020
Global end of trial reached?	Yes
Global end of trial date	20 January 2020
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

This study is designed to 1) describe the safety, tolerability, and immunogenicity of V114 and Prevnar 13™ in pneumococcal vaccine-naïve adults at increased risk for pneumococcal disease and to 2) describe the safety, tolerability, and immunogenicity of PNEUMOVAX™23 when administered 6 months after receipt of either V114 or Prevnar 13™. Increased risk for pneumococcal disease is defined as 1) an underlying medical condition, 2) behavioral habits such as smoking or alcohol use, or 3) living in a community/environment with increased risk of disease transmission.

Protection of trial subjects:

This study was conducted in conformance with Good Clinical Practice standards and applicable country and/or local statutes and regulations regarding ethical committee review, informed consent, and the protection of human subjects participating in biomedical research.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	16 July 2018
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 55
Country: Number of subjects enrolled	Canada: 113
Country: Number of subjects enrolled	Chile: 96
Country: Number of subjects enrolled	New Zealand: 176
Country: Number of subjects enrolled	Poland: 279
Country: Number of subjects enrolled	Russian Federation: 15
Country: Number of subjects enrolled	United States: 781
Worldwide total number of subjects	1515
EEA total number of subjects	279

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0

Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	1515
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

A total of 1515 participants were randomized across 77 study sites. Eligible participants were to be randomly assigned in a 3:1 ratio to receive a single dose of either V114 or Prevnar 13™ on Day 1. Participants also received a single dose of PNEUMOVAX™23 at Month 6.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
Arm title	V114

Arm description:

Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).

Arm type	Experimental
Investigational medicinal product name	V114
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose

Investigational medicinal product name	PNEUMOVAX™23
Investigational medicinal product code	
Other name	PPV23
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose

Investigational medicinal product name	PNEUMOVAX™23
Investigational medicinal product code	
Other name	PPV23
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose

Arm title	Prevnar 13™
------------------	-------------

Arm description:

Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2)

Arm type	Experimental
Investigational medicinal product name	Prevnar 13™
Investigational medicinal product code	
Other name	PCV13
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose

Number of subjects in period 1	V114	Prevnar 13™
Started	1135	380
Vaccination 1-V114 or Prevnar 13™, Day 1	1133	379
Vaccination 2-PNEUMOVAX™23, Month 6	1035 ^[1]	346 ^[2]
Completed	1038	350
Not completed	97	30
Adverse event, serious fatal	4	2
Consent withdrawn by subject	34	12
Screen Failure	-	1
Lost to follow-up	59	15

Notes:

[1] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Participants could have been considered to complete the study without receipt of PNEUMOVAX™23.

[2] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Participants could have been considered to complete the study without receipt of PNEUMOVAX™23.

Baseline characteristics

Reporting groups

Reporting group title	V114
-----------------------	------

Reporting group description:

Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).

Reporting group title	Prevnar 13™
-----------------------	-------------

Reporting group description:

Participants were to receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2)

Reporting group values	V114	Prevnar 13™	Total
Number of subjects	1135	380	1515
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	1135	380	1515
From 65-84 years	0	0	0
85 years and over	0	0	0
Age Continuous			
Units: years			
arithmetic mean	35.9	35.8	-
standard deviation	± 8.9	± 8.9	-
Sex: Female, Male			
Units:			
Female	581	201	782
Male	554	179	733
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	445	148	593
Asian	15	8	23
Native Hawaiian or Other Pacific Islander	33	11	44
Black or African American	43	18	61
White	582	192	774
More than one race	17	3	20
Unknown or Not Reported	0	0	0
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	135	39	174
Not Hispanic or Latino	984	338	1322
Unknown or Not Reported	16	3	19

End points

End points reporting groups

Reporting group title	V114
Reporting group description:	
Participants were to receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).	
Reporting group title	Pevnar 13™
Reporting group description:	
Participants were to receive a single 0.5 mL IM injection of Pevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2)	

Primary: Percentage of Participants with Solicited Injection-site Adverse Events Following V114 or Pevnar 13™

End point title	Percentage of Participants with Solicited Injection-site Adverse Events Following V114 or Pevnar 13™ ^[1]
End point description:	
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Following Vaccination 1 with either V114 or Pevnar 13™ (PCV13), the percentage of participants with solicited injection-site AEs was assessed. The solicited injection-site AEs assessed were redness/erythema, swelling, and tenderness/pain. Estimated confidence intervals (CIs) are calculated based on the exact binomial method proposed by Clopper and Pearson. The analysis population included all randomized participants who received the relevant study vaccination for the timepoint of interest and were included in the intervention group according to the intervention they received. One participant in the Pevnar 13™ group incorrectly received V114 and was included in the V114 group for safety analyses.	
End point type	Primary
End point timeframe:	
Up to 5 days after Vaccination 1	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were planned or conducted for this endpoint.

End point values	V114	Pevnar 13™		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1134	378		
Units: Percentage of Participants				
number (confidence interval 95%)				
Injection site redness/erythema	15.1 (13.0 to 17.3)	14.0 (10.7 to 17.9)		
Injection site tenderness/pain	75.8 (73.2 to 78.3)	68.8 (63.8 to 73.4)		
Injection site swelling	21.7 (19.3 to 24.2)	22.2 (18.1 to 26.8)		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Participants with Solicited Systemic Adverse Events Following V114 or Pevnar 13™

End point title	Percentage of Participants with Solicited Systemic Adverse Events Following V114 or Pevnar 13™ ^[2]
-----------------	---

End point description:

An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Following vaccination with V114 or Pevnar 13™, the percentage of participants with solicited systemic AEs was assessed. The solicited systemic AEs assessed were muscle pain/myalgia, joint pain/arthritis, headache, and tiredness/fatigue. Estimated CIs are calculated based on the exact binomial method proposed by Clopper and Pearson. The analysis population included all randomized participants who received the relevant study vaccination for the timepoint of interest and were included in the intervention group according to the intervention they received. One participant in the Pevnar 13™ group incorrectly received V114 and was included in the V114 group for safety analyses.

End point type	Primary
----------------	---------

End point timeframe:

Up to 14 days after Vaccination 1

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were planned or conducted for this endpoint.

End point values	V114	Pevnar 13™		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1134	378		
Units: Percentage of Participants				
number (confidence interval 95%)				
Joint pain/arthritis	12.7 (10.8 to 14.8)	11.6 (8.6 to 15.3)		
Tiredness/fatigue	34.3 (31.5 to 37.1)	36.8 (31.9 to 41.9)		
Headache	26.5 (23.9 to 29.1)	24.9 (20.6 to 29.5)		
Muscle pain/myalgia	28.8 (26.2 to 31.6)	25.5 (22.1 to 31.2)		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Participants with a Vaccine-related Serious Adverse Event Following V114 or Pevnar 13™

End point title	Percentage of Participants with a Vaccine-related Serious Adverse Event Following V114 or Pevnar 13™ ^[3]
-----------------	---

End point description:

A serious adverse event (SAE) is an AE that is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. Relatedness of an SAE to the study vaccine was determined by the investigator. Following vaccination with V114 or Pevnar 13™, the percentage of serious adverse events of V114 compared with Pevnar 13™ was assessed. Estimated CIs are calculated based on the exact binomial method proposed by Clopper and Pearson. The analysis population included all randomized participants who received the relevant study vaccination for the timepoint of interest and were included in the intervention group according to the intervention they received. One participant in the Pevnar 13™ group incorrectly received V114 and was included in the V114 group for safety analyses.

End point type	Primary
----------------	---------

End point timeframe:

Up to Month 6 (before Vaccination 2)

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were planned or conducted for this endpoint.

End point values	V114	Prevnar 13™		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1134	378		
Units: Percentage of Participants				
number (confidence interval 95%)	0.0 (0.0 to 0.3)	0.0 (0.0 to 0.8)		

Statistical analyses

No statistical analyses for this end point

Primary: Geometric Mean Titer of Serotype-specific Opsonophagocytic Activity Day 30 Following V114 or Prevnar 13™

End point title	Geometric Mean Titer of Serotype-specific Opsonophagocytic Activity Day 30 Following V114 or Prevnar 13™ ^[4]
-----------------	---

End point description:

The geometric mean titer (GMT) of serotype-specific opsonophagocytic activity (OPA) for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using a multiplex opsonophagocytic assay. The within-group 95% CIs are obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution. The analysis population included all randomized participants without protocol deviations that could have substantially impacted the results of the immunogenicity analyses and had sufficient data to perform the analyses.

End point type	Primary
----------------	---------

End point timeframe:

Day 30

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were planned or conducted for this endpoint.

End point values	V114	Prevnar 13™		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1133	379		
Units: Titers				
number (confidence interval 95%)				
Serotype 1 (Shared) (n=1019, 341)	268.6 (243.7 to 296.0)	267.2 (220.4 to 323.9)		
Serotype 3 (Shared) (n=1004, 340)	199.3 (184.6 to 215.2)	150.6 (130.6 to 173.8)		
Serotype 4 (Shared)(n=1016, 342)	1416.0 (1308.9 to 1531.8)	2576.1 (2278.0 to 2913.2)		
Serotype 5 (Shared) (n=1018, 343)	564.8 (512.7 to 622.2)	731.1 (613.6 to 871.0)		
Serotype 6A (Shared) (n=1006, 335)	12928.8 (11923.4 to 14019.0)	11282.4 (9718.8 to 13097.5)		

Serotype 6B (Shared) (n=1014, 342)	10336.9 (9649.4 to 11073.4)	6995.7 (6024.7 to 8123.2)		
Serotype 7F (Shared) (n=1019, 342)	5756.4 (5410.4 to 6124.6)	7588.9 (6775.3 to 8500.2)		
Serotype 9V (Shared) (n=1015, 343)	3355.1 (3135.4 to 3590.1)	3983.7 (3557.8 to 4460.7)		
Serotype 14 (Shared) (n=1016, 343)	5228.9 (4847.6 to 5640.2)	5889.8 (5218.2 to 6647.8)		
Serotype 18C (Shared) (n=1014, 343)	5709.0 (5331.1 to 6113.6)	3063.2 (2699.8 to 3475.5)		
Serotype 19A (Shared) (n=1015, 343)	5369.9 (5017.7 to 5746.8)	5888.0 (5228.2 to 6631.0)		
Serotype 19F (Shared) (n=1018, 343)	3266.3 (3064.4 to 3481.4)	3272.7 (2948.2 to 3632.9)		
Serotype 23F (Shared) (n=1016, 340)	4853.5 (4469.8 to 5270.2)	3887.3 (3335.8 to 4530.0)		
Serotype 22F (Unique to V114) (n=1005, 320)	3926.5 (3645.9 to 4228.7)	291.6 (221.8 to 383.6)		
Serotype 33F (Unique to V114) (n=1014, 338)	11627.8 (10824.6 to 12490.7)	2180.6 (1828.7 to 2600.2)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants with Solicited Injection-site Adverse Events Following PNEUMOVAX® 23

End point title	Percentage of Participants with Solicited Injection-site Adverse Events Following PNEUMOVAX® 23
-----------------	---

End point description:

An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Following Vaccination 2 with PNEUMOVAX® 23 (PPV23), the percentage of participants with solicited injection-site AEs was assessed. The solicited injection-site AEs assessed were redness/erythema, swelling, and tenderness/pain. Estimated CIs are calculated based on the exact binomial method proposed by Clopper and Pearson and are provided in accordance with the statistical analysis plan. All randomized participants who received the relevant study vaccination for the timepoint of interest and were included in the intervention group according to the intervention they received. One participant in the Prevnar 13™ group incorrectly received V114 and was included in the V114 group for safety analyses.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 5 days after Vaccination 2 (Month 6)

End point values	V114	Pprevnar 13™		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1036	345		
Units: Percentage of Participants				
number (confidence interval 95%)				
Injection site redness/erythema	22.6 (20.1 to 25.3)	25.5 (21.0 to 30.5)		
Injection site tenderness/pain	68.8 (65.9 to 71.6)	67.0 (61.7 to 71.9)		
Injection site swelling	29.4 (26.7 to 32.3)	32.2 (27.3 to 37.4)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants with Solicited Systemic Adverse Events Following PNEUMOVAX™23

End point title	Percentage of Participants with Solicited Systemic Adverse Events Following PNEUMOVAX™23
-----------------	--

End point description:

An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Following Vaccination 2 with PNEUMOVAX™23, the percentage of participants with solicited systemic AEs was assessed. The solicited systemic AEs assessed were muscle pain/myalgia, joint pain/arthritis, headache, and tiredness/fatigue. Estimated CIs are calculated based on the exact binomial method proposed by Clopper and Pearson. The analysis population included all randomized participants who received the relevant study vaccination for the timepoint of interest and were included in the intervention group according to the intervention they received. One participant in the Pprevnar 13™ group incorrectly received V114 and was included in the V114 group for safety analyses.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 14 days after Vaccination 2 (Month 6)

End point values	V114	Pprevnar 13™		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1036	345		
Units: Percentage of Participants				
number (confidence interval 95%)				
Joint pain/arthritis	12.0 (10.1 to 14.1)	11.0 (7.9 to 14.8)		
Tiredness/fatigue	30.1 (27.3 to 33.0)	30.7 (25.9 to 35.9)		
Headache	21.2 (18.8 to 23.9)	21.2 (17.0 to 25.9)		
Muscle pain/myalgia	24.1 (21.6 to 26.9)	25.5 (21.0 to 30.5)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants with a Vaccine-related Serious Adverse Event Following PNEUMOVAX™23

End point title	Percentage of Participants with a Vaccine-related Serious Adverse Event Following PNEUMOVAX™23
-----------------	--

End point description:

A serious adverse event (SAE) is an AE that is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. Relatedness of an SAE to the study vaccine was determined by the investigator. Following vaccination with PNEUMOVAX™23, the percentage of serious adverse events of V114 compared with Prevnar 13™ was assessed. Estimated CIs are calculated based on the exact binomial method proposed by Clopper and Pearson. The analysis population included all randomized participants who received the relevant study vaccination for the timepoint of interest and were included in the intervention group according to the intervention they received. One participant in the Prevnar 13™ group incorrectly received V114 and was included in the V114 group for safety analyses.

End point type	Secondary
----------------	-----------

End point timeframe:

From Month 6 (before Vaccination 2) to Month 7

End point values	V114	Prevnar 13™		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1036	345		
Units: Percentage of Participants				
number (confidence interval 95%)	0.0 (0.0 to 0.3)	0.3 (0.0 to 1.6)		

Statistical analyses

No statistical analyses for this end point

Secondary: Geometric Mean Concentration of Serotype-specific Immunoglobulin G at Day 30

End point title	Geometric Mean Concentration of Serotype-specific Immunoglobulin G at Day 30
-----------------	--

End point description:

The geometric mean concentration (GMC) of serotype-specific immunoglobulin G (IgG) for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using an electrochemiluminescence assay. The within-group 95% CIs are obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution. The analysis population included all randomized participants without protocol deviations that could have substantially impacted the results of the immunogenicity analyses and had sufficient data to perform the analyses.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 30

End point values	V114	Prevnam 13™		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1133	379		
Units: µg/mL				
geometric mean (confidence interval 95%)				
Serotype 1 (Shared) (n=1020, 343)	3.56 (3.29 to 3.85)	4.59 (4.00 to 5.26)		
Serotype 3 (Shared) (n=1017, 343)	0.77 (0.72 to 0.83)	0.63 (0.57 to 0.71)		
Serotype 4 (Shared) (n=1015, 343)	1.53 (1.40 to 1.66)	2.71 (2.34 to 3.13)		
Serotype 5 (Shared) (n=1020, 342)	3.43 (3.14 to 3.75)	4.48 (3.77 to 5.32)		
Serotype 6A (Shared) (n=1020, 343)	11.84 (10.71 to 13.10)	10.87 (9.06 to 13.05)		
Serotype 6B (Shared) (n=1020, 342)	17.90 (16.21 to 19.76)	11.36 (9.45 to 13.66)		
Serotype 7F (Shared) (n=1020, 343)	5.18 (4.77 to 5.62)	6.88 (5.95 to 7.95)		
Serotype 9V (Shared) (n=1019, 343)	4.44 (4.11 to 4.80)	5.31 (4.62 to 6.10)		
Serotype 14 (Shared) (n=1020, 343)	15.91 (14.46 to 17.51)	17.35 (14.93 to 20.16)		
Serotype 18C (Shared) (n=1020, 343)	14.57 (13.42 to 15.81)	9.32 (8.06 to 10.79)		
Serotype 19A (Shared) (n=1020, 343)	19.41 (18.00 to 20.93)	21.79 (18.85 to 25.19)		
Serotype 19F (Shared) (n=1018, 343)	13.98 (12.90 to 15.14)	13.35 (11.52 to 15.47)		
Serotype 23F (Shared) (n=1019, 343)	13.57 (12.44 to 14.80)	10.98 (9.34 to 12.91)		
Serotype 22F (Unique to V114) (n=1020, 342)	6.22 (5.74 to 6.74)	0.52 (0.45 to 0.60)		
Serotype 33F (Unique to V114) (n=1020, 342)	7.79 (7.16 to 8.48)	0.88 (0.78 to 1.00)		

Statistical analyses

No statistical analyses for this end point

Secondary: Geometric Mean Fold Rise in Serotype-specific OPA Day 1 to Day 30

End point title	Geometric Mean Fold Rise in Serotype-specific OPA Day 1 to Day 30
-----------------	---

End point description:

Activity for the serotypes contained in Prevnam 13™ and V114 (13 serotypes shared with Prevnam 13™ and 2 serotypes unique to V114) was determined using a Multiplex Opsonophagocytic Assay. Geometric mean fold rise (GMFR) is the geometric mean of fold rise from baseline to postvaccination. The analysis population included all randomized participants without protocol deviations that could have substantially impacted the results of the immunogenicity analyses and had sufficient data to perform the analyses.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 (Baseline) and Day 30

End point values	V114	Prevnar 13™		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1133	379		
Units: Ratio				
geometric mean (confidence interval 95%)				
Serotype 1 (Shared) (n=1001, 334)	22.8 (20.6 to 25.1)	21.9 (18.4 to 26.2)		
Serotype 3 (Shared) (n=982, 329)	5.8 (5.4 to 6.3)	4.8 (4.3 to 5.5)		
Serotype 4 (Shared) (n=988, 329)	17.9 (16.2 to 19.8)	33.4 (28.1 to 39.7)		
Serotype 5 (Shared) (n=1003, 337)	17.3 (15.7 to 18.9)	21.1 (18.0 to 24.7)		
Serotype 6A (Shared) (n=910, 298)	21.7 (19.6 to 23.9)	21.4 (18.0 to 25.5)		
Serotype 6B (Shared) (n=969, 328)	32.2 (28.6 to 36.3)	25.0 (20.6 to 30.5)		
Serotype 7F (Shared) (n=945, 318)	7.3 (6.6 to 8.2)	10.0 (8.3 to 12.0)		
Serotype 9V (Shared) (n=977, 332)	4.9 (4.5 to 5.3)	5.7 (5.0 to 6.6)		
Serotype 14 (Shared) (n=973, 331)	8.2 (7.4 to 9.2)	8.7 (7.2 to 10.6)		
Serotype 18C (Shared) (n=973, 331)	20.4 (18.6 to 22.4)	11.7 (10.1 to 13.6)		
Serotype 19A (Shared) (n=975, 326)	12.5 (11.3 to 13.9)	13.6 (11.4 to 16.2)		
Serotype 19F (Shared) (n=985, 329)	7.5 (6.9 to 8.2)	7.4 (6.4 to 8.6)		
Serotype 23F (Shared) (n=945, 310)	22.5 (20.0 to 25.4)	17.8 (14.6 to 21.7)		
Serotype 22F (Unique to V114)(n=885, 290)	13.9 (11.8 to 16.3)	1.3 (1.1 to 1.6)		
Serotype 33F (Unique to V114) (n=979, 326)	5.4 (4.9 to 5.9)	1.0 (0.8 to 1.1)		

Statistical analyses

No statistical analyses for this end point

Secondary: GMFR in Serotype-specific IgG Day 1 to Day 30

End point title	GMFR in Serotype-specific IgG Day 1 to Day 30
End point description: IgG for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using an electrochemiluminescence assay. GMFR is the geometric mean of fold rise from baseline to postvaccination. The analysis population included all randomized participants without protocol deviations that could have substantially impacted the results of the immunogenicity analyses and had sufficient data to perform the analyses.	
End point type	Secondary

End point timeframe:

Day 1 (Baseline) and Day 30

End point values	V114	Prevnar 13™		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1133	379		
Units: Ratio				
geometric mean (confidence interval 95%)				
Serotype 1 (Shared) (n=1007, 338)	12.2 (11.3 to 13.2)	15.7 (13.9 to 17.8)		
Serotype 3 (Shared) (n=1004, 338)	4.1 (3.8 to 4.3)	3.6 (3.2 to 4.0)		
Serotype 4 (Shared) (n=1001, 338)	8.0 (7.4 to 8.6)	16.2 (14.3 to 18.4)		
Serotype 5 (Shared) (n=1007, 337)	4.3 (4.0 to 4.7)	5.2 (4.5 to 6.0)		
Serotype 6A (Shared) (n=1007, 338)	35.5 (32.5 to 38.8)	31.3 (26.7 to 36.6)		
Serotype 6B (Shared) (n=1006, 338)	40.5 (37.1 to 44.2)	28.0 (24.2 to 32.4)		
Serotype 7F (Shared) (n=1007, 338)	12.2 (11.3 to 13.2)	16.9 (14.8 to 19.3)		
Serotype 9V (Shared) (n=1006, 338)	10.6 (9.8 to 11.4)	12.8 (11.3 to 14.5)		
Serotype 14 (Shared) (n=1007, 338)	11.3 (10.3 to 12.5)	11.5 (9.7 to 13.7)		
Serotype 18C (Shared) (n=1007, 338)	30.5 (28.0 to 33.1)	20.0 (17.2 to 23.2)		
Serotype 19A (Shared) (n=1007, 338)	11.1 (10.2 to 12.0)	14.0 (12.2 to 16.0)		
Serotype 19F (Shared) (n=1005, 338)	14.4 (13.2 to 15.7)	15.3 (13.1 to 17.7)		
Serotype 23F (Shared) (n=1006, 338)	26.5 (24.2 to 29.0)	22.0 (19.0 to 25.5)		
Serotype 22F (Unique to V114) (n=1007, 337)	11.4 (10.4 to 12.6)	1.0 (1.0 to 1.1)		
Serotype 33F (Unique to V114) (n=1007, 337)	8.3 (7.7 to 8.9)	1.0 (1.0 to 1.0)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants with ≥4-Fold Rise in Serotype-specific OPA Day 1 to Day 30

End point title	Percentage of Participants with ≥4-Fold Rise in Serotype-specific OPA Day 1 to Day 30
-----------------	---

End point description:

Activity for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using a Multiplexed Opsonophagocytic Assay. The percentage of participants who had ≥4-fold rise in OPA titers were calculated from baseline to postvaccination. The analysis population included all randomized participants without protocol deviations that could have substantially impacted the results of the immunogenicity analyses and had sufficient data to perform the analyses.

End point type	Secondary
End point timeframe:	
Day 1 (Baseline) and Day 30	

End point values	V114	Prevnar 13™		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1133	379		
Units: Percentage of Participants				
number (confidence interval 95%)				
Serotype 1 (Shared) (n=1001, 334)	83.9 (81.5 to 86.1)	81.4 (76.8 to 85.5)		
Serotype 3 (Shared) (n=982, 329)	62.2 (59.1 to 65.3)	56.8 (51.3 to 62.3)		
Serotype 4 (Shared) (n=988, 329)	79.0 (76.4 to 81.5)	87.8 (83.8 to 91.2)		
Serotype 5 (Shared) (n=1003, 337)	83.4 (81.0 to 85.7)	84.9 (80.6 to 88.5)		
Serotype 6A (Shared) (n=910, 298)	87.5 (85.1 to 89.6)	85.2 (80.7 to 89.1)		
Serotype 6B (Shared) (n=969, 328)	84.7 (82.3 to 86.9)	83.8 (79.4 to 87.7)		
Serotype 7F (Shared) (n=945, 318)	56.8 (53.6 to 60.0)	64.5 (58.9 to 69.7)		
Serotype 9V (Shared) (n=977, 332)	51.5 (48.3 to 54.7)	55.4 (49.0 to 60.8)		
Serotype 14 (Shared) (n=973, 331)	59.8 (56.7 to 62.9)	60.4 (54.9 to 65.7)		
Serotype 18C (Shared) (n=973, 331)	84.5 (82.1 to 86.7)	75.8 (70.8 to 80.3)		
Serotype 19A (Shared) (n=975, 326)	72.1 (69.2 to 74.9)	75.2 (70.1 to 79.8)		
Serotype 19F (Shared) (n=985, 329)	64.3 (61.2 to 67.3)	65.7 (60.2 to 70.8)		
Serotype 23F (Shared) (n=945, 310)	78.7 (76.0 to 81.3)	77.7 (72.7 to 82.2)		
Serotype 22F (Unique to V114) (n=885, 290)	58.9 (55.5 to 62.1)	15.5 (11.5 to 20.2)		
Serotype 33F (Unique to V114) (n=979, 326)	52.9 (49.7 to 56.1)	3.1 (1.5 to 5.6)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants with ≥4-Fold Rise in Serotype-specific IgG Day 1 to Day 30

End point title	Percentage of Participants with ≥4-Fold Rise in Serotype-specific IgG Day 1 to Day 30
-----------------	---

End point description:

IgG for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using an electrochemiluminescence assay. The percentage of participants who had ≥ 4-fold rise in IgG concentration are calculated from baseline to postvaccination.

The analysis population included all randomized participants without protocol deviations that could have substantially impacted the results of the immunogenicity analyses and had sufficient data to perform the analyses.

End point type	Secondary
End point timeframe:	
Day 1 (Baseline) and Day 30	

End point values	V114	Prevnar 13™		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1133	379		
Units: Percentage of Participants				
number (confidence interval 95%)				
Serotype 1 (Shared) (n=1007, 338)	81.2 (78.7 to 83.6)	86.4 (82.3 to 89.9)		
Serotype 3 (Shared) (n=1004, 338)	44.8 (41.7 to 48.0)	41.1 (35.8 to 46.6)		
Serotype 4 (Shared) (n=1001, 338)	70.1 (67.2 to 73.0)	86.1 (81.9 to 89.6)		
Serotype 5 (Shared) (n=1007, 337)	44.1 (41.0 to 47.2)	50.4 (45.0 to 55.9)		
Serotype 6A (Shared) (n=1007, 338)	93.3 (91.6 to 94.8)	88.2 (84.2 to 91.4)		
Serotype 6B (Shared) (n=1006, 337)	93.4 (91.7 to 94.9)	90.5 (86.9 to 93.4)		
Serotype 7F (Shared) (n=1007, 338)	79.3 (76.7 to 81.8)	86.4 (82.3 to 89.9)		
Serotype 9V (Shared) (n=1006, 338)	76.5 (73.8 to 79.1)	84.0 (79.7 to 87.8)		
Serotype 14 (Shared) (n=1007, 338)	70.8 (67.9 to 73.6)	68.6 (63.4 to 73.6)		
Serotype 18C (Shared) (n=1007, 338)	91.1 (89.1 to 92.8)	87.3 (83.2 to 90.6)		
Serotype 19A (Shared) (n=1007, 338)	75.3 (72.5 to 77.9)	82.0 (77.4 to 85.9)		
Serotype 19F (Shared) (n=1005, 338)	80.0 (77.4 to 82.4)	80.8 (76.2 to 84.8)		
Serotype 23F (Shared) (n=1006, 338)	89.2 (87.1 to 91.0)	87.6 (83.6 to 90.9)		
Serotype 22F (Unique to V114) (n=1007, 337)	73.1 (70.2 to 75.8)	1.5 (0.5 to 3.4)		
Serotype 33F (Unique to V114) (n=1007, 337)	70.0 (67.1 to 72.8)	0.3 (0.0 to 1.6)		

Statistical analyses

No statistical analyses for this end point

Secondary: Geometric Mean Titer of Serotype-specific OPA at Month 7

End point title	Geometric Mean Titer of Serotype-specific OPA at Month 7
End point description:	
The geometric mean titer (GMT) of serotype-specific OPA for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined	

using a multiplex opsonophagocytic assay. The within-group 95% CIs are obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution. The analysis population included all randomized participants without protocol deviations that could have substantially impacted the results of the immunogenicity analyses and had sufficient data to perform the analyses.

End point type	Secondary
End point timeframe:	
Month 7	

End point values	V114	Prevnar 13™		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1133	379		
Units: Titers				
number (confidence interval 95%)				
Serotype 1 (Shared) (n=841, 281)	266.6 (243.6 to 291.8)	214.4 (180.7 to 254.5)		
Serotype 3 (Shared) (n=837, 279)	211.0 (195.2 to 228.1)	208.0 (179.7 to 240.7)		
Serotype 4 (Shared) (n=840, 283)	1734.5 (1620.7 to 1856.4)	1980.6 (1771.3 to 2214.6)		
Serotype 5 (Shared) (n=844, 283)	595.1 (544.5 to 650.5)	626.7 (531.7 to 738.7)		
Serotype 6A (Shared) (n=830, 276)	5810.3 (5366.9 to 6290.3)	5739.9 (4974.4 to 6623.1)		
Serotype 6B (Shared) (n=843, 283)	5215.2 (4863.6 to 5592.2)	4412.4 (3892.8 to 5001.5)		
Serotype 7F (Shared) (n=843, 283)	6070.5 (5699.7 to 6465.6)	6223.9 (5595.3 to 6923.0)		
Serotype 9V (Shared) (n=842, 282)	3133.1 (2918.4 to 3363.7)	3364.1 (2972.2 to 3807.6)		
Serotype 14 (Shared) (n=843, 283)	5644.9 (5262.5 to 6055.2)	5317.6 (4686.1 to 6034.1)		
Serotype 18C (Shared) (n=842, 281)	3260.6 (3057.3 to 3477.5)	2294.4 (2052.5 to 2564.8)		
Serotype 19A (Shared) (n=836, 283)	4336.2 (4038.6 to 4655.6)	4286.4 (3838.6 to 4786.4)		
Serotype 19F (Shared) (n=844, 282)	3198.6 (3011.0 to 3397.8)	3085.4 (2770.7 to 3435.9)		
Serotype 23F (Shared) (n=839, 283)	3057.3 (2823.0 to 3311.0)	2896.0 (2494.1 to 3362.7)		
Serotype 22F (Unique to V114) (n=837, 280)	3624.0 (3384.5 to 3880.3)	4060.2 (3358.6 to 4908.4)		
Serotype 33F (Unique to V114) (n=837, 282)	11356.6 (10492.4 to 12291.9)	16053.2 (13688.1 to 18827.1)		

Statistical analyses

No statistical analyses for this end point

Secondary: Geometric Mean Concentration of Serotype-specific IgG at Month 7

End point title	Geometric Mean Concentration of Serotype-specific IgG at Month 7
-----------------	--

End point description:

The geometric mean concentration (GMC) of serotype-specific immunoglobulin G (IgG) for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using an electrochemiluminescence assay. The analysis population included all randomized participants without protocol deviations that could have substantially impacted the results of the immunogenicity analyses and had sufficient data to perform the analyses.

End point type	Secondary
----------------	-----------

End point timeframe:

Month 7

End point values	V114	Prevnar 13™		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1133	379		
Units: µg/mL				
geometric mean (confidence interval 95%)				
Serotype 1 (Shared) (n=844, 283)	2.91 (2.71 to 3.12)	3.42 (3.02 to 3.87)		
Serotype 3 (Shared) (n=844, 283)	0.66 (0.62 to 0.71)	0.68 (0.61 to 0.76)		
Serotype 4 (Shared) (n=843, 281)	1.33 (1.23 to 1.44)	1.77 (1.55 to 2.02)		
Serotype 5 (Shared) (n=844, 283)	3.45 (3.17 to 3.75)	3.92 (3.37 to 4.56)		
Serotype 6A (Shared) (n=843, 283)	4.25 (3.84 to 4.69)	4.88 (4.08 to 5.85)		
Serotype 6B (Shared) (n=844, 283)	6.79 (6.15 to 7.49)	6.04 (5.08 to 7.19)		
Serotype 7F (Shared) (n=844, 283)	3.46 (3.36 to 3.94)	4.07 (3.54 to 4.68)		
Serotype 9V (Shared) (n=844, 283)	3.18 (2.96 to 3.43)	3.61 (3.17 to 4.12)		
Serotype 14 (Shared) (n=844, 283)	14.28 (13.13 to 15.53)	14.59 (12.64 to 16.85)		
Serotype 18C (Shared) (n=844, 283)	5.50 (5.07 to 5.98)	4.24 (3.71 to 4.84)		
Serotype 19A (Shared) (n=844, 283)	11.26 (10.47 to 12.11)	12.04 (10.57 to 13.72)		
Serotype 19F (Shared) (n=844, 283)	9.07 (8.45 to 9.74)	8.81 (7.74 to 10.02)		

Serotype 23F (Shared) (n=844, 282)	5.42 (4.98 to 5.89)	4.96 (4.25 to 5.81)		
Serotype 22F (Unique to V114) (n=844, 283)	4.85 (4.50 to 5.23)	4.76 (4.01 to 5.65)		
Serotype 33F (Unique to V114) (n=844, 283)	5.98 (5.50 to 6.50)	8.66 (7.31 to 10.26)		

Statistical analyses

No statistical analyses for this end point

Secondary: GMFR in Serotype-specific OPA Day 1 to Month 7

End point title	GMFR in Serotype-specific OPA Day 1 to Month 7
End point description:	
Activity for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using a Multiplexed Opsonophagocytic Assay. Geometric mean fold rise (GMFR) is the geometric mean of fold rise from baseline to postvaccination. The analysis population included all randomized participants without protocol deviations that could have substantially impacted the results of the immunogenicity analyses and had sufficient data to perform the analyses.	
End point type	Secondary
End point timeframe:	
Day 1 (Baseline) and Month 7	

End point values	V114	Prevnar 13™		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1133	379		
Units: Ratio				
geometric mean (confidence interval 95%)				
Serotype 1 (Shared) (n=826, 276)	22.6 (20.6 to 24.8)	17.4 (14.8 to 20.5)		
Serotype 3 (Shared) (n=820, 270)	6.1 (5.6 to 6.6)	6.4 (5.6 to 7.3)		
Serotype 4 (Shared) (n=820, 273)	21.6 (19.5 to 23.9)	25.6 (21.7 to 30.3)		
Serotype 5 (Shared) (n=831, 279)	17.8 (16.3 to 19.3)	18.3 (15.8 to 21.1)		
Serotype 6A (Shared) (n=754, 247)	9.6 (8.7 to 10.5)	11.0 (9.3 to 13.0)		
Serotype 6B (Shared) (n=802, 273)	16.6 (14.7 to 18.7)	15.7 (12.8 to 19.2)		
Serotype 7F (Shared) (n=777, 264)	7.7 (6.9 to 8.6)	8.2 (6.7 to 9.9)		
Serotype 9V (Shared) (n=810, 273)	4.5 (4.2 to 4.9)	4.9 (4.2 to 5.7)		
Serotype 14 (Shared) (n=809, 275)	9.2 (8.2 to 10.3)	8.0 (6.6 to 9.7)		
Serotype 18C (Shared) (n=805, 273)	11.1 (10.2 to 12.2)	9.1 (7.9 to 10.5)		
Serotype 19A (Shared) (n=806, 271)	9.6 (8.6 to 10.6)	9.7 (8.1 to 11.6)		
Serotype 19F (Shared) (n=818, 272)	6.9 (6.3 to 7.6)	7.1 (6.1 to 8.3)		
Serotype 23F (Shared) (n=780, 260)	14.0 (12.4 to 15.7)	12.6 (10.3 to 15.4)		

Serotype 22F (Unique to V114) (n=742, 254)	12.1 (10.4 to 14.3)	16.6 (12.2 to 22.6)		
Serotype 33F (Unique to V114) (n=810, 273)	5.1 (4.6 to 5.7)	6.6 (5.5 to 8.0)		

Statistical analyses

No statistical analyses for this end point

Secondary: GMFR in Serotype-specific IgG Day 1 to Month 7

End point title	GMFR in Serotype-specific IgG Day 1 to Month 7
End point description:	
IgG for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using an electrochemiluminescence assay. GMFR is the geometric mean of fold rise from baseline to postvaccination. The analysis population included all randomized participants without protocol deviations that could have substantially impacted the results of the immunogenicity analyses and had sufficient data to perform the analyses.	
End point type	Secondary
End point timeframe:	
Day 1 (Baseline) and Month 7	

End point values	V114	Prevnar 13™		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1133	379		
Units: Ratio				
geometric mean (confidence interval 95%)				
Serotype 1 (Shared) (n=833, 280)	10.1 (9.4 to 10.8)	11.4 (10.1 to 12.8)		
Serotype 3 (Shared) (n=833, 280)	3.5 (3.3 to 3.7)	3.8 (3.4 to 4.2)		
Serotype 4 (Shared) (n=830, 278)	7.1 (6.7 to 7.6)	10.7 (9.5 to 12.0)		
Serotype 5 (Shared) (n=833, 280)	4.3 (4.0 to 4.8)	4.6 (4.1 to 5.2)		
Serotype 6A (Shared) (n=832, 280)	12.3 (11.3 to 13.4)	13.9 (12.0 to 16.1)		
Serotype 6B (Shared) (n=832, 280)	15.3 (14.1 to 16.6)	14.9 (13.0 to 17.0)		
Serotype 7F (Shared) (n=833, 280)	8.7 (8.1 to 9.3)	10.1 (9.0 to 11.3)		
Serotype 9V (Shared) (n=833, 280)	7.6 (7.1 to 8.1)	8.5 (7.6 to 9.5)		
Serotype 14 (Shared) (n=833, 280)	10.3 (9.4 to 11.3)	10.0 (8.5 to 11.8)		
Serotype 18C (Shared) (n=833, 280)	11.5 (10.7 to 12.4)	9.3 (8.2 to 10.4)		
Serotype 19A (Shared) (n=833, 280)	6.4 (6.0 to 6.9)	7.5 (6.7 to 8.5)		
Serotype 19F (Shared) (n=833, 280)	9.0 (8.3 to 9.7)	9.8 (8.6 to 11.2)		
Serotype 23F (Shared) (n=833, 279)	10.8 (9.9 to 11.7)	10.3 (9.0 to 11.7)		
Serotype 22F (Unique to V114) (n=833, 280)	8.9 (8.1 to 9.7)	8.9 (7.5 to 10.7)		

Serotype 33F (Unique to V114) (n=833, 280)	6.4 (6.0 to 6.9)	9.6 (8.4 to 11.1)		
--	------------------	-------------------	--	--

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants with ≥ 4 -Fold Rise in Serotype-specific OPA Day 1 to Month 7

End point title	Percentage of Participants with ≥ 4 -Fold Rise in Serotype-specific OPA Day 1 to Month 7
End point description: Activity for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using a Multiplexed Opsonophagocytic Assay. The percentage of participants who had ≥ 4 -fold rise in OPA titers were calculated from baseline to postvaccination. The analysis population included all randomized participants without protocol deviations that could have substantially impacted the results of the immunogenicity analyses and had sufficient data to perform the analyses.	
End point type	Secondary
End point timeframe: Day 1 (Baseline) and Month 7	

End point values	V114	Prevnar 13™		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1133	379		
Units: Percentage of Participants				
number (confidence interval 95%)				
Serotype 1 (Shared) (n=826, 276)	87.7 (85.2 to 89.8)	83.7 (78.8 to 87.9)		
Serotype 3 (Shared) (n=820, 270)	66.5 (63.1 to 69.7)	66.7 (60.7 to 72.3)		
Serotype 4 (Shared) (n=820, 273)	84.3 (81.6 to 86.7)	86.4 (81.8 to 90.3)		
Serotype 5 (Shared) (n=831, 279)	86.8 (84.3 to 89.0)	87.1 (82.6 to 90.8)		
Serotype 6A (Shared) (n=754, 247)	73.5 (70.2 to 76.6)	80.2 (74.6 to 84.9)		
Serotype 6B (Shared) (n=802, 273)	75.8 (72.7 to 78.7)	74.4 (68.7 to 79.4)		
Serotype 7F (Shared) (n=777, 264)	59.8 (56.3 to 63.3)	60.2 (54.0 to 66.2)		
Serotype 9V (Shared) (n=810, 273)	50.5 (47.0 to 54.0)	52.4 (46.3 to 58.4)		
Serotype 14 (Shared) (n=809, 275)	64.9 (61.5 to 68.2)	58.9 (52.8 to 64.8)		
Serotype 18C (Shared) (n=805, 273)	77.5 (74.5 to 80.4)	76.2 (70.7 to 81.1)		
Serotype 19A (Shared) (n=806, 271)	68.2 (64.9 to 71.4)	70.5 (64.7 to 75.8)		
Serotype 19F (Shared) (n=818, 272)	61.0 (57.6 to 64.4)	62.9 (56.8 to 68.6)		

Serotype 23F (Shared) (n=780, 260)	73.5 (70.2 to 76.5)	71.9 (66.0 to 77.3)		
Serotype 22F (Unique to V114) (n=742, 254)	59.0 (55.4 to 62.6)	65.4 (59.2 to 71.2)		
Serotype 33F (Unique to V114) (n=810, 273)	53.3 (49.8 to 56.8)	60.8 (54.7 to 66.6)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants with ≥ 4 -Fold Rise in Serotype-specific IgG Day 1 to Month 7

End point title	Percentage of Participants with ≥ 4 -Fold Rise in Serotype-specific IgG Day 1 to Month 7
End point description: IgG for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using an electrochemiluminescence assay. The percentage of participants who had ≥ 4 -fold rise in IgG concentration are calculated from baseline to postvaccination. The analysis population included all randomized participants without protocol deviations that could have substantially impacted the results of the immunogenicity analyses and had sufficient data to perform the analyses.	
End point type	Secondary
End point timeframe: Day 1 (Baseline) and Month 7	

End point values	V114	Prevnar 13™		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1133	379		
Units: Percentage of Participants				
number (confidence interval 95%)				
Serotype 1 (Shared) (n=833, 280)	81.4 (78.6 to 84.0)	83.6 (78.7 to 87.7)		
Serotype 3 (Shared) (n=833, 280)	40.7 (37.3 to 44.1)	46.1 (40.1 to 52.1)		
Serotype 4 (Shared) (n=830, 278)	71.2 (68.0 to 74.3)	82.0 (77.0 to 86.3)		
Serotype 5 (Shared) (n=833, 280)	48.7 (45.3 to 52.2)	51.8 (45.8 to 57.8)		
Serotype 6A (Shared) (n=832, 280)	81.6 (78.8 to 84.2)	81.8 (76.8 to 86.1)		
Serotype 6B (Shared) (n=832, 280)	86.4 (83.9 to 88.7)	85.4 (80.7 to 89.3)		
Serotype 7F (Shared) (n=833, 280)	77.4 (74.4 to 80.2)	84.3 (79.5 to 88.3)		
Serotype 9V (Shared) (n=833, 280)	71.8 (68.6 to 74.8)	77.1 (71.8 to 81.9)		
Serotype 14 (Shared) (n=833, 280)	76.7 (73.7 to 79.5)	70.7 (65.0 to 76.0)		
Serotype 18C (Shared) (n=833, 280)	82.7 (80.0 to 85.2)	80.4 (75.2 to 84.8)		

Serotype 19A (Shared) (n=833, 280)	65.8 (62.5 to 69.0)	74.6 (69.1 to 79.6)		
Serotype 19F (Shared) (n=833, 280)	74.5 (71.4 to 77.5)	78.9 (73.7 to 83.6)		
Serotype 23F (Shared) (n=833, 279)	77.8 (74.8 to 80.6)	78.1 (72.8 to 82.8)		
Serotype 22F (Unique to V114) (n=833, 280)	68.8 (65.5 to 71.9)	65.7 (59.8 to 71.3)		
Serotype 33F (Unique to V114) (n=833, 280)	68.2 (64.9 to 71.3)	75.7 (70.3 to 80.6)		

Statistical analyses

No statistical analyses for this end point

Secondary: GMFR in Serotype-specific OPA Month 6 to Month 7

End point title	GMFR in Serotype-specific OPA Month 6 to Month 7
End point description:	
Activity for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using the Multiplexed Opsonophagocytic Assay. Geometric mean fold rise (GMFR) is the geometric mean of fold rise from baseline to postvaccination. The analysis population included all randomized participants without protocol deviations that could have substantially impacted the results of the immunogenicity analyses and had sufficient data to perform the analyses.	
End point type	Secondary
End point timeframe:	
Month 6 (Baseline before Vaccination 2) and Month 7	

End point values	V114	Prevnar 13™		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1133	379		
Units: Ratio				
geometric mean (confidence interval 95%)				
Serotype 1 (Shared) (n=839, 280)	3.2 (2.9 to 3.5)	2.0 (1.7 to 2.2)		
Serotype 3 (Shared) (n=826, 274)	2.0 (1.9 to 2.1)	2.4 (2.2 to 2.7)		
Serotype 4 (Shared) (n=837, 281)	2.7 (2.5 to 2.9)	1.7 (1.5 to 1.9)		
Serotype 5 (Shared) (n=840, 282)	2.7 (2.5 to 2.9)	2.1 (1.9 to 2.4)		
Serotype 6A (Shared) (n=818, 270)	1.0 (1.0 to 1.1)	1.1 (1.0 to 1.2)		
Serotype 6B (Shared) (n=842, 280)	1.1 (1.1 to 1.2)	1.2 (1.1 to 1.4)		
Serotype 7F (Shared) (n=837, 281)	1.9 (1.8 to 2.0)	1.4 (1.3 to 1.6)		
Serotype 9V (Shared) (n=835, 278)	1.6 (1.5 to 1.7)	1.5 (1.4 to 1.7)		
Serotype 14 (Shared) (n=841, 280)	2.0 (1.8 to 2.1)	1.5 (1.3 to 1.6)		
Serotype 18C (Shared) (n=839, 279)	1.3 (1.3 to 1.4)	1.6 (1.4 to 1.7)		
Serotype 19A (Shared) (n=830, 282)	1.7 (1.6 to 1.8)	1.5 (1.4 to 1.7)		
Serotype 19F (Shared) (n=843, 280)	1.9 (1.8 to 2.0)	1.6 (1.5 to 1.8)		
Serotype 23F (Shared) (n=837, 280)	1.3 (1.2 to 1.4)	1.4 (1.2 to 1.6)		
Serotype 22F (Unique to V114) (n=822, 253)	1.8 (1.7 to 1.9)	9.6 (7.1 to 13.0)		

Serotype 33F (Unique to V114) (n=834, 278)	1.6 (1.5 to 1.8)	6.5 (5.5 to 7.6)		
--	------------------	------------------	--	--

Statistical analyses

No statistical analyses for this end point

Secondary: GMFR in Serotype-specific IgG Month 6 to Month 7

End point title	GMFR in Serotype-specific IgG Month 6 to Month 7
-----------------	--

End point description:

IgG for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using an electrochemiluminescence assay. GMFR is the geometric mean of fold rise from baseline to postvaccination. The analysis population included all randomized participants without protocol deviations that could have substantially impacted the results of the immunogenicity analyses and had sufficient data to perform the analyses.

End point type	Secondary
----------------	-----------

End point timeframe:

Month 6 (Baseline before Vaccination 2) and Month 7

End point values	V114	Prevnar 13™		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1133	379		
Units: Ratio				
geometric mean (confidence interval 95%)				
Serotype 1 (Shared) (n=843, 282)	2.1 (2.0 to 2.2)	1.5 (1.4 to 1.7)		
Serotype 3 (Shared) (n=842, 282)	1.7 (1.6 to 1.7)	2.0 (1.8 to 2.1)		
Serotype 4 (Shared) (n=840, 280)	2.0 (1.9 to 2.1)	1.6 (1.5 to 1.7)		
Serotype 5 (Shared) (n=843, 282)	1.9 (1.8 to 1.9)	1.5 (1.4 to 1.6)		
Serotype 6A (Shared) (n=842, 282)	1.0 (1.0 to 1.0)	1.0 (1.0 to 1.1)		
Serotype 6B (Shared) (n=843, 282)	1.1 (1.0 to 1.1)	1.2 (1.2 to 1.3)		
Serotype 7F (Shared) (n=843, 282)	1.7 (1.6 to 1.8)	1.4 (1.3 to 1.5)		
Serotype 9V (Shared) (n=841, 282)	1.5 (1.5 to 1.6)	1.4 (1.3 to 1.5)		
Serotype 14 (Shared) (n=843, 282)	1.7 (1.6 to 1.8)	1.4 (1.3 to 1.5)		
Serotype 18C (Shared) (n=843, 282)	1.1 (1.0 to 1.1)	1.1 (1.1 to 1.2)		
Serotype 19A (Shared) (n=842, 282)	1.4 (1.3 to 1.4)	1.4 (1.3 to 1.4)		
Serotype 19F (Shared) (n=843, 282)	1.6 (1.6 to 1.7)	1.6 (1.5 to 1.7)		
Serotype 23F (Shared) (n=842, 281)	1.1 (1.1 to 1.2)	1.2 (1.1 to 1.2)		
Serotype 22F (Unique to V114) (n=843, 282)	1.8 (1.7 to 1.9)	8.8 (7.4 to 10.4)		
Serotype 33F (Unique to V114) (n=843, 282)	1.6 (1.6 to 1.7)	9.9 (8.6 to 11.3)		

Statistical analyses

Secondary: Percentage of Participants with ≥ 4 -Fold Rise in Serotype-specific OPA Month 6 to Month 7

End point title	Percentage of Participants with ≥ 4 -Fold Rise in Serotype-specific OPA Month 6 to Month 7
End point description:	
Activity for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using a Multiplexed Opsonophagocytic Assay. The percentage of participants who had ≥ 4 -fold rise in OPA titers were calculated from baseline to postvaccination. The analysis population included all randomized participants without protocol deviations that could have substantially impacted the results of the immunogenicity analyses and had sufficient data to perform the analyses.	
End point type	Secondary
End point timeframe:	
Month 6 (Baseline before Vaccination 2) and Month 7	

End point values	V114	Prevnar 13™		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1133	379		
Units: Percentage of Participants				
number (confidence interval 95%)				
Serotype 1 (Shared) (n=839, 280)	40.2 (36.8 to 43.6)	21.4 (16.8 to 26.7)		
Serotype 3 (Shared) (n=826, 274)	19.2 (16.6 to 22.1)	25.5 (20.5 to 31.1)		
Serotype 4 (Shared) (n=837, 281)	30.8 (27.7 to 34.1)	14.9 (11.0 to 19.7)		
Serotype 5 (Shared) (n=840, 282)	32.5 (29.3 to 35.8)	23.0 (18.3 to 28.4)		
Serotype 6A (Shared) (n=818, 270)	3.9 (2.7 to 5.5)	5.9 (3.4 to 9.4)		
Serotype 6B (Shared) (n=842, 280)	4.6 (3.3 to 6.3)	6.4 (3.9 to 10.0)		
Serotype 7F (Shared) (n=837, 281)	14.6 (12.3 to 17.2)	7.5 (4.7 to 11.2)		
Serotype 9V (Shared) (n=835, 278)	11.9 (9.7 to 14.2)	10.4 (7.1 to 14.6)		
Serotype 14 (Shared) (n=841, 280)	17.8 (15.3 to 20.6)	8.6 (5.6 to 12.5)		
Serotype 18C (Shared) (n=839, 279)	5.4 (3.9 to 7.1)	14.3 (10.4 to 19.0)		
Serotype 19A (Shared) (n=830, 282)	15.9 (13.5 to 18.6)	12.1 (8.5 to 16.4)		
Serotype 19F (Shared) (n=843, 280)	17.7 (15.2 to 20.4)	12.9 (9.2 to 17.4)		
Serotype 23F (Shared) (n=837, 280)	9.2 (7.3 to 11.4)	11.4 (7.9 to 15.7)		
Serotype 22F (Unique to V114) (n=822, 253)	16.7 (14.2 to 19.4)	52.6 (46.2 to 58.9)		
Serotype 33F (Unique to V114) (n=834, 278)	15.8 (13.4 to 18.5)	62.6 (56.6 to 68.3)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants with ≥ 4 -Fold Rise in Serotype-specific IgG Month 6 to Month 7

End point title	Percentage of Participants with ≥ 4 -Fold Rise in Serotype-specific IgG Month 6 to Month 7
End point description:	
IgG for the serotypes contained in Prevnar 13™ and V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using an electrochemiluminescence assay. The percentage of participants who had ≥ 4 -fold rise in IgG concentration are calculated from baseline to postvaccination. The analysis population included all randomized participants without protocol deviations that could have substantially impacted the results of the immunogenicity analyses and had sufficient data to perform the analyses.	
End point type	Secondary
End point timeframe:	
Month 6 (Baseline before Vaccination 2) and Month 7	

End point values	V114	Prevnar 13™		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1133	379		
Units: Percentage of Participants				
number (confidence interval 95%)				
Serotype 1 (Shared) (n=843, 282)	16.4 (13.9 to 19.0)	8.2 (5.2 to 12.0)		
Serotype 3 (Shared) (n=842, 282)	6.3 (4.8 to 8.2)	13.8 (10.0 to 18.4)		
Serotype 4 (Shared) (n=840, 280)	15.2 (12.9 to 17.8)	7.5 (4.7 to 11.2)		
Serotype 5 (Shared) (n=843, 282)	12.1 (10.0 to 14.5)	5.7 (3.3 to 9.1)		
Serotype 6A (Shared) (n=842, 282)	0.6 (0.2 to 1.4)	1.1 (0.2 to 3.1)		
Serotype 6B (Shared) (n=843, 282)	0.7 (0.3 to 1.5)	2.8 (1.2 to 5.5)		
Serotype 7F (Shared) (n=843, 282)	8.4 (6.6 to 10.5)	4.3 (2.2 to 7.3)		
Serotype 9V (Shared) (n=841, 282)	6.3 (4.8 to 8.2)	3.9 (2.0 to 6.9)		
Serotype 14 (Shared) (n=843, 282)	9.8 (7.9 to 12.1)	3.9 (2.0 to 6.9)		
Serotype 18C (Shared) (n=843, 282)	0.6 (0.2 to 1.4)	0.7 (0.1 to 2.5)		
Serotype 19A (Shared) (n=842, 282)	3.4 (2.3 to 4.9)	4.3 (2.2 to 7.3)		
Serotype 19F (Shared) (n=843, 282)	8.1 (6.3 to 10.1)	6.4 (3.8 to 9.9)		
Serotype 23F (Shared) (n=842, 281)	0.5 (0.1 to 1.2)	1.1 (0.2 to 3.1)		
Serotype 22F (Unique to V114) (n=843, 282)	10.2 (8.2 to 12.4)	64.9 (59.0 to 70.5)		
Serotype 33F (Unique to V114) (n=843, 282)	7.5 (5.8 to 9.5)	75.9 (70.5 to 80.8)		

Statistical analyses

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Non-serious adverse events: Up to 14 days after each vaccination; Serious adverse events and all-cause mortality: Up to Month 7 (Up to 44 days after vaccination 2).

Adverse event reporting additional description:

The analysis population included all randomized participants who received the relevant study vaccination for the timepoint of interest and were included in the intervention group according to the intervention they received. One participant in the Pevnar 13™ group incorrectly received V114 and was included in the V114 group for safety analyses.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
Dictionary version	23.0

Reporting groups

Reporting group title	V114
-----------------------	------

Reporting group description:

Participants received a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).

Reporting group title	Pevnar 13™
-----------------------	------------

Reporting group description:

Participants received a single 0.5 mL IM injection of Pevnar 13™ on Day 1 (Vaccination 1) and were to receive a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).

Reporting group title	V114 (Post-PNEUMOVAX™23)
-----------------------	--------------------------

Reporting group description:

Participants received a single 0.5 mL IM injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).

Reporting group title	Pevnar 13™ (Post-PNEUMOVAX™23)
-----------------------	--------------------------------

Reporting group description:

Participants received a single 0.5 mL IM injection of Pevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2).

Serious adverse events	V114	Pevnar 13™	V114 (Post-PNEUMOVAX™23)
Total subjects affected by serious adverse events			
subjects affected / exposed	49 / 1134 (4.32%)	12 / 378 (3.17%)	3 / 1036 (0.29%)
number of deaths (all causes)	4	2	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Colon cancer			
subjects affected / exposed	1 / 1134 (0.09%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endometrial cancer			

subjects affected / exposed	1 / 1134 (0.09%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal neoplasm			
subjects affected / exposed	1 / 1134 (0.09%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Uterine leiomyoma			
subjects affected / exposed	2 / 1134 (0.18%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Hypertensive urgency			
subjects affected / exposed	1 / 1134 (0.09%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	1 / 1134 (0.09%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	1 / 1134 (0.09%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Non-cardiac chest pain			
subjects affected / exposed	0 / 1134 (0.00%)	1 / 378 (0.26%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Anaphylactic reaction			
subjects affected / exposed	1 / 1134 (0.09%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Social circumstances			
Physical assault			
subjects affected / exposed	1 / 1134 (0.09%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Pelvic pain			
subjects affected / exposed	1 / 1134 (0.09%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	2 / 1134 (0.18%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleuritic pain			
subjects affected / exposed	1 / 1134 (0.09%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia aspiration			
subjects affected / exposed	1 / 1134 (0.09%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	1 / 1134 (0.09%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Alcohol withdrawal syndrome			
subjects affected / exposed	1 / 1134 (0.09%)	0 / 378 (0.00%)	1 / 1036 (0.10%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Completed suicide			

subjects affected / exposed	1 / 1134 (0.09%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Drug dependence			
subjects affected / exposed	0 / 1134 (0.00%)	1 / 378 (0.26%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicidal ideation			
subjects affected / exposed	0 / 1134 (0.00%)	1 / 378 (0.26%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicide attempt			
subjects affected / exposed	1 / 1134 (0.09%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Clavicle fracture			
subjects affected / exposed	1 / 1134 (0.09%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eyelid injury			
subjects affected / exposed	0 / 1134 (0.00%)	1 / 378 (0.26%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Facial bones fracture			
subjects affected / exposed	1 / 1134 (0.09%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hand fracture			
subjects affected / exposed	1 / 1134 (0.09%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple injuries			

subjects affected / exposed	1 / 1134 (0.09%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Skin laceration			
subjects affected / exposed	1 / 1134 (0.09%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tibia fracture			
subjects affected / exposed	1 / 1134 (0.09%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Craniocerebral injury			
subjects affected / exposed	0 / 1134 (0.00%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Angina unstable			
subjects affected / exposed	1 / 1134 (0.09%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure			
subjects affected / exposed	0 / 1134 (0.00%)	1 / 378 (0.26%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Cardiovascular insufficiency			
subjects affected / exposed	1 / 1134 (0.09%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congestive cardiomyopathy			
subjects affected / exposed	0 / 1134 (0.00%)	1 / 378 (0.26%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulseless electrical activity			

subjects affected / exposed	0 / 1134 (0.00%)	1 / 378 (0.26%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute left ventricular failure			
subjects affected / exposed	0 / 1134 (0.00%)	0 / 378 (0.00%)	1 / 1036 (0.10%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac arrest			
subjects affected / exposed	1 / 1134 (0.09%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	1 / 1134 (0.09%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhagic stroke			
subjects affected / exposed	0 / 1134 (0.00%)	1 / 378 (0.26%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Hepatic encephalopathy			
subjects affected / exposed	1 / 1134 (0.09%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
IIIrd nerve paralysis			
subjects affected / exposed	1 / 1134 (0.09%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Migraine			
subjects affected / exposed	1 / 1134 (0.09%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subarachnoid haemorrhage			

subjects affected / exposed	3 / 1134 (0.26%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Generalised tonic-clonic seizure			
subjects affected / exposed	0 / 1134 (0.00%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 1134 (0.00%)	0 / 378 (0.00%)	1 / 1036 (0.10%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Ascites			
subjects affected / exposed	1 / 1134 (0.09%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric ulcer haemorrhage			
subjects affected / exposed	1 / 1134 (0.09%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric ulcer perforation			
subjects affected / exposed	1 / 1134 (0.09%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			
subjects affected / exposed	1 / 1134 (0.09%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestine perforation			
subjects affected / exposed	0 / 1134 (0.00%)	1 / 378 (0.26%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstructive pancreatitis			

subjects affected / exposed	0 / 1134 (0.00%)	1 / 378 (0.26%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis acute			
subjects affected / exposed	1 / 1134 (0.09%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Bile duct stone			
subjects affected / exposed	1 / 1134 (0.09%)	1 / 378 (0.26%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis			
subjects affected / exposed	0 / 1134 (0.00%)	1 / 378 (0.26%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis acute			
subjects affected / exposed	2 / 1134 (0.18%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholelithiasis			
subjects affected / exposed	0 / 1134 (0.00%)	1 / 378 (0.26%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	2 / 1134 (0.18%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrolithiasis			
subjects affected / exposed	1 / 1134 (0.09%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrotic syndrome			

subjects affected / exposed	1 / 1134 (0.09%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Diabetes insipidus			
subjects affected / exposed	1 / 1134 (0.09%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Goitre			
subjects affected / exposed	1 / 1134 (0.09%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Rheumatoid arthritis			
subjects affected / exposed	1 / 1134 (0.09%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Diverticulitis			
subjects affected / exposed	0 / 1134 (0.00%)	1 / 378 (0.26%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	1 / 1134 (0.09%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Groin abscess			
subjects affected / exposed	1 / 1134 (0.09%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematoma infection			
subjects affected / exposed	1 / 1134 (0.09%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Influenza			
subjects affected / exposed	0 / 1134 (0.00%)	1 / 378 (0.26%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Localised infection			
subjects affected / exposed	1 / 1134 (0.09%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis			
subjects affected / exposed	1 / 1134 (0.09%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Periorbital cellulitis			
subjects affected / exposed	1 / 1134 (0.09%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Perirectal abscess			
subjects affected / exposed	1 / 1134 (0.09%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonsillitis			
subjects affected / exposed	1 / 1134 (0.09%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pharyngitis streptococcal			
subjects affected / exposed	1 / 1134 (0.09%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	1 / 1134 (0.09%)	1 / 378 (0.26%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative wound infection			

subjects affected / exposed	1 / 1134 (0.09%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	2 / 1134 (0.18%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 1134 (0.00%)	1 / 378 (0.26%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hypoglycaemia			
subjects affected / exposed	1 / 1134 (0.09%)	0 / 378 (0.00%)	0 / 1036 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Prevnar 13™ (Post-PNEUMOVAX™23)		
Total subjects affected by serious adverse events			
subjects affected / exposed	3 / 345 (0.87%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Colon cancer			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Endometrial cancer			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal neoplasm			

subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Uterine leiomyoma			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
Hypertensive urgency			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypotension			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	1 / 345 (0.29%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Non-cardiac chest pain			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Immune system disorders			
Anaphylactic reaction			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Social circumstances			
Physical assault			

subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Reproductive system and breast disorders			
Pelvic pain			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pleuritic pain			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumonia aspiration			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pulmonary embolism			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
Alcohol withdrawal syndrome			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Completed suicide			

subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Drug dependence			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Suicidal ideation			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Suicide attempt			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Clavicle fracture			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Eyelid injury			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Facial bones fracture			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hand fracture			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Multiple injuries			

subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Skin laceration			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tibia fracture			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Craniocerebral injury			
subjects affected / exposed	1 / 345 (0.29%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Angina unstable			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac failure			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiovascular insufficiency			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Congestive cardiomyopathy			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pulseless electrical activity			

subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Acute left ventricular failure			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac arrest			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haemorrhagic stroke			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatic encephalopathy			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
IIIrd nerve paralysis			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Migraine			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Subarachnoid haemorrhage			

subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Generalised tonic-clonic seizure			
subjects affected / exposed	1 / 345 (0.29%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Syncope			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Ascites			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastric ulcer haemorrhage			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastric ulcer perforation			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Inguinal hernia			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Large intestine perforation			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Obstructive pancreatitis			

subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pancreatitis acute			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
Bile duct stone			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cholecystitis			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cholecystitis acute			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cholelithiasis			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nephrolithiasis			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nephrotic syndrome			

subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Endocrine disorders			
Diabetes insipidus			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Goitre			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Rheumatoid arthritis			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Diverticulitis			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastroenteritis			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Groin abscess			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haematoma infection			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Influenza				
subjects affected / exposed	0 / 345 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Localised infection				
subjects affected / exposed	0 / 345 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Meningitis				
subjects affected / exposed	0 / 345 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Periorbital cellulitis				
subjects affected / exposed	0 / 345 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Perirectal abscess				
subjects affected / exposed	0 / 345 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Peritonsillitis				
subjects affected / exposed	0 / 345 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pharyngitis streptococcal				
subjects affected / exposed	0 / 345 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumonia				
subjects affected / exposed	0 / 345 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Postoperative wound infection				

subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pyelonephritis			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sepsis			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Hypoglycaemia			
subjects affected / exposed	0 / 345 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	V114	Prevnar 13™	V114 (Post-PNEUMOVAX™23)
Total subjects affected by non-serious adverse events			
subjects affected / exposed	934 / 1134 (82.36%)	298 / 378 (78.84%)	771 / 1036 (74.42%)
Nervous system disorders			
Headache			
subjects affected / exposed	300 / 1134 (26.46%)	94 / 378 (24.87%)	220 / 1036 (21.24%)
occurrences (all)	425	122	274
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	389 / 1134 (34.30%)	139 / 378 (36.77%)	312 / 1036 (30.12%)
occurrences (all)	510	186	366
Injection site erythema			
subjects affected / exposed	174 / 1134 (15.34%)	56 / 378 (14.81%)	235 / 1036 (22.68%)
occurrences (all)	180	57	237
Injection site pain			

subjects affected / exposed	865 / 1134 (76.28%)	260 / 378 (68.78%)	714 / 1036 (68.92%)
occurrences (all)	931	292	762
Injection site swelling			
subjects affected / exposed	251 / 1134 (22.13%)	84 / 378 (22.22%)	305 / 1036 (29.44%)
occurrences (all)	257	84	307
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	144 / 1134 (12.70%)	44 / 378 (11.64%)	124 / 1036 (11.97%)
occurrences (all)	180	63	130
Myalgia			
subjects affected / exposed	327 / 1134 (28.84%)	100 / 378 (26.46%)	250 / 1036 (24.13%)
occurrences (all)	377	113	260

Non-serious adverse events	Prevnar 13™ (Post-PNEUMOVAX™23)		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	258 / 345 (74.78%)		
Nervous system disorders			
Headache			
subjects affected / exposed	73 / 345 (21.16%)		
occurrences (all)	93		
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	106 / 345 (30.72%)		
occurrences (all)	139		
Injection site erythema			
subjects affected / exposed	88 / 345 (25.51%)		
occurrences (all)	91		
Injection site pain			
subjects affected / exposed	231 / 345 (66.96%)		
occurrences (all)	252		
Injection site swelling			
subjects affected / exposed	113 / 345 (32.75%)		
occurrences (all)	113		
Musculoskeletal and connective tissue disorders			

Arthralgia			
subjects affected / exposed	38 / 345 (11.01%)		
occurrences (all)	47		
Myalgia			
subjects affected / exposed	88 / 345 (25.51%)		
occurrences (all)	99		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
21 June 2018	Amendment 01: The primary purpose of this amendment is to remove the collection of medical device incidents from the protocol.
18 September 2018	Amendment 02: The primary purpose of this amendment is to include a spirometry assessment at Visit 1 for those who have a clinical history of asthma or chronic obstructive pulmonary disease (COPD) and who do not have spirometry results from within the previous 5 years.
07 May 2019	Amendment 03: The primary purpose of this amendment is to include country-specific requirements for the Ministry of Healthcare (MoH) of the Russian Federation.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported